<DOC>
	<DOCNO>NCT02189343</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) , present , dose schedule ACY-1215 ( ricolinostat ) combination pomalidomide low-dose dexamethasone patient relapsed-and-refractory multiple myeloma .</brief_summary>
	<brief_title>Phase 1b Study Evaluating ACY-1215 ( Ricolinostat ) Combination With Pomalidomide Dexamethasone Relapsed Relapsed-and-Refractory Multiple Myeloma</brief_title>
	<detailed_description>To determine maximum tolerate dose ( MTD ) , present , identify recommend dose schedule ricolinostat administer alternative liquid formulation ( ALF ) ( 10mg/mL ) combination pomalidomide low-dose dexamethasone patient relapse relapsed-and-refractory multiple myeloma . To evaluate safety anti-tumor activity ricolinostat administer combination pomalidomide dexamethasone treatment patient relapse relapsed-and-refractory multiple myeloma , include duration response . To assess Pharmacokinetics Pharmacodynamics three medication administer combination , assess Pharmacokinetics ricolinostat pomalidomide specifically . An evaluation relationship response biomarkers relate interacellular acetylation may also complete .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Key Inclusion Criteria Includes : Patients meet follow criterion may enrol study : 1 . Must able understand voluntarily sign ICF . 2 . Must register mandatory POMALYST Risk Evaluation Mitigation Strategy ( REMS ) ™ program , willing able comply requirement POMALYST REMS™ program ( Appendix 9.3 ) . 3 . Must ≥ 18 year age time sign ICF . 4 . Must able adhere study visit schedule protocol requirement . 5 . Must document diagnosis MM relapse relapsed refractory disease . Patients must receive least 2 line prior therapy . Patients must relapse achieve least stable disease least 1 cycle treatment least 1 prior regimen develop PD . Relapsed relapsedandrefractory patient must document evidence PD within 60 day ( measure end last cycle ) complete treatment last antimyeloma drug regimen use prior study entry . 6 . Patients must undergo prior treatment least 2 cycle lenalidomide least 2 cycle proteasome inhibitor ( either separate regimen within regimen . 7 . Must candidate autologous stem cell transplant ( ASCT ) , decline option ASCT , relapse prior ASCT . 8 . Must measurable level myeloma paraprotein serum ( ≥ 0.5 g/dL ) urine ( ≥ 0.2 g/24 hour ) . Patients myeloma paraprotein must serum free light chain ( SFLC ) concentration ≥ 10 mg/dL , provide SFLC ratio abnormal . Nonsecretory myeloma exclude . 9 . Must Eastern Cooperative Oncology Group performance status score 0 , 1 , 2 . 10 . Females childbearing potential must negative serum urine pregnancy test describe Appendix 9.3 POMALYST REMS™ program . Females childbearing potential male must either commit continue abstinence heterosexual intercourse must abide birth control requirement describe Appendix 9.3 POMALYST REMS™ program . 11 . Must agree refrain donate blood study drug 28 day discontinuation study . 12 . Must agree share study medication another person . 13 . Must able take ASA ( 81 325 mg ) daily prophylactic anticoagulation . Patients intolerant ASA may use low molecular weight heparin . Lovenox recommend . Coumadin allow provide patient fully anticoagulated , international normalize ratio 2 3 . Key Exclusion Criteria Includes : Patients meet follow criterion exclude enrollment study : 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent patient sign ICF follow study requirement . 2 . Pregnant lactating female . 3 . Prior therapy histone deacetylase inhibitor pomalidomide . 4 . Any following laboratory abnormality : ANC &lt; 1,000/µL Platelet count &lt; 75,000/ µL patient &lt; 50 % bone marrow nucleate cell plasma cell , platelet count &lt; 50,000 patient ≥ 50 % bone marrow nucleate cell plasma cell Hemoglobin &lt; 8 g/dL ( &lt; 4.9 mmol/L ; prior red blood cell transfusion recombinant human erythropoietin use permit ) . Creatinine clearance &lt; 45 mL/min accord CockcroftGault formula . If creatinine clearance calculate 24 hour urine sample ≥ 45 mL/min , patient qualify trial . Serum glutamic oxaloacetic transaminase/aspartate aminotransferase , serum glutamic pyruvic transaminase/alanine aminotransferase &gt; 3.0 × ULN Serum total bilirubin &gt; 2.0 mg/dL 5 . Prior history malignancy , MM , unless patient free disease ≥ 3 year . Exceptions include follow : Basal squamous cell carcinoma skin Ductal carcinoma situ ; cervical intraepithelial neoplasia Carcinoma prostate current prostatespecific antigen upper limit normal 6 . Corrected QT interval ( QTc ) use Fridericia 's formula value &gt; 480 msec Screening ; family personal history long QTc syndrome ventricular arrhythmia include ventricular bigeminy Screening ; previous history druginduced QTc prolongation need treatment medication know suspected produce prolonged QTc interval electrocardiogram . 7 . Known human immunodeficiency virus , hepatitis B virus , know suspect active hepatitis C virus infection . 8 . Hypersensitivity thalidomide , lenalidomide , pomalidomide , dexamethasone ( Steven Johnson Syndrome ) . Hypersensitivity , rash , medically manage allowable . 9 . Peripheral neuropathy ≥ Grade 2 despite supportive therapy . 10 . Radiotherapy systemic therapy ( standard investigational biologic anticancer agent ) within 14 day initiation study drug treatment . 11 . Current enrollment another clinical trial involve treatment and/or receive investigational agent reason . 12 . Inability unwillingness comply birth control requirement POMALYST REMS™ requirement per Appendix 9.3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Refractory</keyword>
	<keyword>Refractory Disease</keyword>
	<keyword>Progressive Disease</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Proteasome Inhibitor</keyword>
	<keyword>Ricolinostat</keyword>
</DOC>